Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02495623 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Phase 2 study, sponsored by Theriva Biologics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02495623 is a Phase 2 study that has completed, run by Theriva Biologics. The registered enrollment target is 63 participants.
The verdict
NCT02495623, a Phase 2 study, has completed, sponsored by Theriva Biologics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with Irritable Bowel Syndrome with Constipation (IBS-C)
Interventions
- DRUG Placebo
- DRUG SYN-010 21 mg
- DRUG SYN-010 42 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02495623
The ClinicalTrials.gov registry entry for NCT02495623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theriva Biologics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02495623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02495623 about?
NCT02495623 is a clinical study titled "A Study of the Effect of SYN-010 on Subjects With IBS-C". A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with Irritable Bowel Syndrome with Constipation (IBS-C)
What is the current status of trial NCT02495623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2015-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02495623?
The interventions under investigation include: Placebo (DRUG), SYN-010 21 mg (DRUG), SYN-010 42 mg (DRUG).
Who is sponsoring clinical trial NCT02495623?
This trial is sponsored by Theriva Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.